Avery D. Posey
YOU?
Author Swipe
View article: Deciphering the Glycan and Protein Interactome of Siglec-15: Unraveling its Role in Tumor-Associated Immunosuppression 2949
Deciphering the Glycan and Protein Interactome of Siglec-15: Unraveling its Role in Tumor-Associated Immunosuppression 2949 Open
Description Immunotherapy has revolutionized cancer treatment, driving interest in strategies to counteract immune suppression within the tumor microenvironment. Siglec-15, a member of the sialic acid-binding immunoglobulin-like lectin fam…
View article: Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies Open
Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. Development of chimeric antigen receptor (CAR) T-cells agai…
View article: Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma
Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma Open
Traditional viral-based chimeric antigen receptor (CAR) T cell therapies have vanquished multiple blood malignancies with decade-long remissions yet struggle against solid tumors. Nonviral engineering of CAR T cells via electroporation or …
View article: Constructing the cure: engineering the next wave of antibody and cellular immune therapies
Constructing the cure: engineering the next wave of antibody and cellular immune therapies Open
Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in hematologic malignancies and select soli…
View article: Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee
Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee Open
Cancer is rapidly on the rise as a cause of morbidity and mortality in low- and middle-income countries (LMICs). However, despite the increasing importance of immune checkpoint inhibitors (ICIs) as a pillar of cancer therapy, access in the…
View article: LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma
LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma Open
Ewing Sarcoma (EwS) is a rare pediatric malignancy characterized by a unique t(11:22) (q24;q12) translocation resulting in the pathognomonic EWSR1::FLI1 fusion. Recent reports indicate that the EWSR1::FLI1 oncofusion drives aberrant expres…
View article: 227 High-dimensional spectral cytometry paired with computational technology provides insights into the cellular features of healthy donor blood products to accelerate allogeneic cell therapy development
227 High-dimensional spectral cytometry paired with computational technology provides insights into the cellular features of healthy donor blood products to accelerate allogeneic cell therapy development Open
View article: CD5 deletion enhances the antitumor activity of adoptive T cell therapies
CD5 deletion enhances the antitumor activity of adoptive T cell therapies Open
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several …
View article: Future perspectives on engineered T cells for cancer
Future perspectives on engineered T cells for cancer Open
Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment for hematological malignancies, but its adaptation to solid tumors is impeded by multiple challenges, particularly T cell dysfunction and exhaustion. T…
View article: Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision Open
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chime…
View article: Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly <i>O</i> -glycosylated Proteins
Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly <i>O</i> -glycosylated Proteins Open
The lack of antibodies with sufficient cancer selectivity is currently limiting the treatment of solid tumors by immunotherapies. Most current immunotherapeutic targets are tumor-associated antigens that are also found in healthy tissues a…
View article: Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma Open
A challenge when targeting T-cell lymphoma with chimeric antigen receptor (CAR) T-cell therapy is that target antigens are often shared between T cells and tumor cells, resulting in fratricide between CAR T cells and on-target cytotoxicity…
View article: Supplemental Table S2 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Supplemental Table S2 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
S2. Comprehensive list of all adverse events based on CTCAE v4.0 grading from Day -2 (IT injection) to Day +25.
View article: Data from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Data from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells Open
This study compared second-generation chimeric antigen receptors (CAR) encoding signaling domains composed of CD28, ICOS, and 4-1BB (TNFRSF9). Here, we report that certain CARs endow T cells with the ability to undergo long-term autonomous…
View article: Data from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Data from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells Open
This study compared second-generation chimeric antigen receptors (CAR) encoding signaling domains composed of CD28, ICOS, and 4-1BB (TNFRSF9). Here, we report that certain CARs endow T cells with the ability to undergo long-term autonomous…
View article: Supplemental Information and Legends from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Supplemental Information and Legends from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
Supplemental Information and Legends
View article: Data from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Data from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T cells. Although successful in treatment of hematologic malignancies, CAR T cells are ineffective for solid tumors to date. We found that the cell-…
View article: Supplementary Figures 1 and 2 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
Supplementary Figures 1 and 2 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager Open
S1. Therapeutic index of EGFR-targeting CART cells and the OAd-BiTE. S2. The Combination of FR-CART cells and OAd-BiTE mediates tumor regression in mice bearing pancreatic xenograft tumors.
View article: Supplemental Table S2 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Supplemental Table S2 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
S2. Comprehensive list of all adverse events based on CTCAE v4.0 grading from Day -2 (IT injection) to Day +25.
View article: Supplemental Methods, Tables 1 - 3, Figures 1 - 16 from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Supplemental Methods, Tables 1 - 3, Figures 1 - 16 from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells Open
Table S1: Expression of c-Met and Mesothelin mRNA in activated CD4 T Cells. Table S2: Genes upregulated in CD4+ T cells of healthy human adults expressing c-Met IgG4 continuous CAR or CD19 CD8α non-continuous CAR on day 11. Table S3: Genes…
View article: Supplemental Table S3 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Supplemental Table S3 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
S3. Serial quantification of serum IL6 from a patient with prolonged subjectove myalgia post IT injection of mRNA c-Met CAR T cells.
View article: Supplementary Figures 1 and 2 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
Supplementary Figures 1 and 2 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager Open
S1. Therapeutic index of EGFR-targeting CART cells and the OAd-BiTE. S2. The Combination of FR-CART cells and OAd-BiTE mediates tumor regression in mice bearing pancreatic xenograft tumors.
View article: Supplemental Table S1 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Supplemental Table S1 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
S1. Association of c-Met positive breast cancer with prognostic variables.
View article: Table S1 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
Table S1 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager Open
The file contains the supplementary table S1
View article: Supplemental Table S3 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Supplemental Table S3 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
S3. Serial quantification of serum IL6 from a patient with prolonged subjectove myalgia post IT injection of mRNA c-Met CAR T cells.
View article: Figures S1 - S5 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Figures S1 - S5 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
S1. Clinical trial schema. S2. Representative immunohistochemistry (IHC). S3. Histology and IHC of tumor tissue pre and post intratumoral injection of RNA CAR T c- Met from one patient. S4. Histology and IHC of tumor tissue pre and post in…
View article: Data from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Data from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T cells. Although successful in treatment of hematologic malignancies, CAR T cells are ineffective for solid tumors to date. We found that the cell-…
View article: Table S1 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
Table S1 from Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager Open
The file contains the supplementary table S1
View article: Supplemental Methods, Tables 1 - 3, Figures 1 - 16 from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Supplemental Methods, Tables 1 - 3, Figures 1 - 16 from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells Open
Table S1: Expression of c-Met and Mesothelin mRNA in activated CD4 T Cells. Table S2: Genes upregulated in CD4+ T cells of healthy human adults expressing c-Met IgG4 continuous CAR or CD19 CD8α non-continuous CAR on day 11. Table S3: Genes…
View article: Figures S1 - S5 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Figures S1 - S5 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer Open
S1. Clinical trial schema. S2. Representative immunohistochemistry (IHC). S3. Histology and IHC of tumor tissue pre and post intratumoral injection of RNA CAR T c- Met from one patient. S4. Histology and IHC of tumor tissue pre and post in…